Von Hippel-Lindau (VHL) disease: An update on the clinico-pathologic and genetic aspects

Advances in Anatomic Pathology

Volumn 15, Issue 3, 2008, Pages 165-171

  Shehata, Bahig M ^a,c   Stockwell, Christina A ^a   Castellano Sanchez, Amilcar A ^a   Setzer, Shannon ^a   Schmotzer, Christine L ^a   Robinson, Haynes ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AKRON CHILDREN'S HOSPITAL   (United States)

^c Children's Healthcare of Atlanta Egleston ^*  (United States)

Author keywords

Genetics; Pathology; Von Hippel Lindau disease

Indexed keywords

CANCER SUSCEPTIBILITY; CYSTADENOMA; DISEASE COURSE; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HEMANGIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; KIDNEY CYST; MOLECULAR GENETICS; PANCREAS DISEASE; PATHOGENESIS; PATHOLOGY; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; VON HIPPEL LINDAU DISEASE;

GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 42549160999     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31816f852e     Document Type: Review

References (69)

1. Maher ER, Yates JRW, Harries R, et al. Clinical features and natural history of von Hippel Lindau disease. Q J Med. 1990;77:1151-1163.
2. Maher ER, Moore AT. von Hippel-Lindau disease. Br J Ophthalmol. 1992;76:743-745.
3. Neumann HPH, Zbar B. Renal cysts, renal cancer and von Hippel-Lindau disease. Kid Int. 1997;51:16-26.
4. Couch V, Lindor MS, Noralane M, et al. von Hippel-Lindau disease. Mayo Clin Proc. 2000;75:265-272.
5. Richard S, Campello C, Talliender L, et al. Haemangioblastoma of the central nervous system in von Hippel Lindau disease. French vHL Study Group. J Intern Med. 1998;243:547-553.
6. Choyke PL, Glenn GM, Wagner JP, et al. Epididymal cystadenomas in von Hippel-Lindau disease. Urology. 1997;49:926-931.
7. Maher ER. von Hippel-Lindau disease. Eur J Cancer. 1994;30:1987-1990.
8. Choyke PL, Glenn GM, Walther MM, et al. von Hippel-Lindau disease: genetic, clinical and imaging features. Radiology. 1995;194:629-642.
9. Gutjahr P. von Hippel-Lindau disease. Neurosurg Rev. 2000;23:23.
10. Braffman B, Naidich TP. The phakomatoses: part II: von Hippel-Lindau disease, Sturge Weber syndrome, and less common conditions. Neuroimaging Clin North Am. 1994;4:325-348.
11. Decker HJH, Weidt EJ, Brieger J. The von-Hippel-Lindau tumor suppressor gene: a rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. Cancer Genet Cytogenet. 1997;93:74-83.
12. Gauthier D, D'Amico DJ, Mukai S. von Hippel-Lindau disease. Int Ophthalmol Clin. 2001;41:173-187.
13. Melmon KL, Rosen SW. Lindau's disease. Am J Med. 1964;36:595.
14. Enterline DS, Davey NC, Tien RD, et al. von Hippel-Lindau disease. AJR. 1995;165:212-213.
15. Ogasawara KK, Ogasawara EM, Hirata G. Pregnancy complicated by von Hippel-Lindau disease. Obst Gynecol. 1995;85:829-831.
16. Vortmeyer AO, Gnarra JR, Emmert-Buck MR, et al. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol. 1997;28:540-543.
17. Polydrides AD, Rosenblum MK, Edgar MA. Metastatic renal cell carcinoma to hemangioblastoma in von Hippel-Lindau disease. Arch Pathol Lab Med. 2007;131:641-645.
18. Sobottka SB, Frank S, Hampl M, et al. Multiple intracerebral haemangioblastomas in identical twins with von Hippel-Lindau disease: a Clinical and Molecular Study. Acta Neurochir. 1998;140:281-285.
19. Jung SM, Kuo TT. Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. Mod Pathol. 2005;18:788-794.
20. North PE, Mizeracki A, Mihm MC Jr, et al. GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma. Clin Neuropathol. 2000;19:131-137.
21. Maher ER, Kaelin WG. von Hippel-Lindau disease. Medicine. 1997;76:381-391.
22. Maher ER. Inherited renal cell carcinoma. Br J Urol. 1996;78:542-545.
23. Chauveau D, Duvic C, Chrétien Y, et al. Renal involvement in von Hippel-Lindau disease. Kidney Intern. 1996;50:944-951.
24. Paraf F, Chauveau D, Chretien Y, et al. Renal lesions in von Hippel-Lindau disease: immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins. Histopathology. 2000;36:457-465.
25. Eng CH, Crossey PA, Mulligan LM, et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumor suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet. 1995;32:934-937.
26. Richards M. Molecular pathology of von Hippel-Lindau disease and the VHL tumour suppressor gene. Expert Rev Mol Med. Available at: http://www-ermm.cbcu.cam.ac.uk.
27. Sawka AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Endocrinol Metab. 2003;88:553-558.
28. Gross DJ, Avishai A, Meiner V, et al. Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J Clin Endocrinol Metab. 1996;81:147-149.
29. Ritter MM, Frilling A, Crossey PA, et al. Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. J Clin Endocrol Metab. 1996;81:1035-1037.
30. Kogire M, Hosotani R, Kondo M, et al. Pancreatic lesions in von Hippel-Lindau syndrome: the coexistence of metastatic tumors from renal cell carcinoma and multiple cysts. Surg Today. 2000;30:380-382.
31. Chen TY, Su CH, Shyr YM, et al. Management of pancreatic lesions in von Hippel-Lindau disease. World J Surg. 1997;21:307-312.
32. Gaffey MJ, Mills SE, Fechner RE, et al. Aggressive papillary middle ear tumor: a clinicopathologic entity distinct from middle-ear adenoma. Am J Surg Pathol. 1988;12:790-797.
33. Megerian CA, McKenna MJ, Nuss RC, et al. Endolymphatic sac tumors: histopathologic conformation, clinical characterization, an implication in von Hippel-Lindau disease. Laryngoscope. 1995;105:801-808.
34. Heffner DK. Low-grade adenocarcinoma of probable endolymphatic sac origin: a clinicopathologic study of 20 cases. Cancer. 1989;64:2292-2302.
35. Manski TJ, Heffner DK, Glenn GM, et al. Endolymphatic sac tumors: a source of morbid hearing loss in von Hippel-Lindau disease. JAMA. 1997;277:1461-1466.
36. Kilmartin DJ, Mooney DJ, Acheson RW, et al. von Hippel-Lindau disease and familial polyposis coli in the same family. Arch Ophthalmol. 1996;114:1294.
37. Kempermann G, Neumann HPH, Scheremet R, et al. Deafness due to bilateral endolymphatic sac tumors in a case of von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry. 1996;61:318-320.
38. Werness BA, Guccion JC. Tumor of the broad ligament in von Hippel-Lindau disease of probable Mullerian origin. Int J Gynecol Pathol. 1997;16:282-285.
39. Scheithauer BW, Parameswaran A, Burdick B. Intrasellar paraganglioma: a report of a case in a sibship of von Hippel-Lindau disease. Neurosurgery. 1996;38:395-398.
40. Tenner S, Roston A, Lichtenstein D, et al. von Hippel-Lindau disease complicated by acute pancreatitis and Evan's syndrome. Int J Pancreatol. 1995;18:271-275.
41. So CC, Ho L. Polycythemia secondary to cerebellar hemangioblastoma. Am J Hematol. 2002;71:346-347.
42. Maddock IR, Moran A, Maher ER, et al. A genetic register for von Hippel Lindau disease. J Med Genet. 1996;33:120-127.
43. Yang H, Kaelin WG Jr. Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing. Cell Growth Diff. 2001;12:447-455.
44. Lesho EP. Recognition and management of von Hippel-Lindau disease. Am Fam Phys. 1994;50:1269-1272.
45. Sims KB. von Hippel-Lindau disease: gene to bedside. Curr Opin Neurol. 2001;14:695-703.
46. Shuin T, Yamasaki I, Tamura K, et al. von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol. 2006;36:337-343.
47. Chan CC, Collins AB, Chew EY. Molecular pathology of eyes with von Hippel-Lindau (VHL) disease: a review. Retina. 2007;27:1-7.
48. Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res. 2001;264:117-125.
49. Ohh M. Ubiquitin pathway in VHL cancer syndrome. Neoplasia. 2006;8:623-629.
50. Kaelin WG Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol. 2003;14:2703-2711.
51. Kaelin WG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007;13:680s-684s.
52. Weirich G, Klein B, Wohl T, et al. VHL2C phenotype in a German von Hippel-Lindau family with concurrent VHL germline mutations P81S and L188V. J Clin Endoc Metab. 2002;87:5241-5246.
53. Kibel A, Iliopulos O, DeCaprio J, et al. Binding of the von Hippel-Lindau suppressor protein to elongin B and C. Science. 1995;269:1444-1446.
54. Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;1:237-246.
55. Pause S, Lee RA, Worrell DYT, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA. 1997;94:2156-2161.
56. Maher ER. "VHL and von Hippel-Lindau Disease." Inborn Errors of Development: the Molecular Basis of Clinical Disorders of Morphogenesis. New York: Oxford University Press; 2004:823-827.
57. Clifford S, Cockman ME, Smallwood AC, et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 2001;10:1029-1038.
58. Ohh M, Takagi Y, Aso T, et al. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest. 1999;104:1583-1591.
59. Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol. 2004;287:F1-F6.
60. 2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
61. Maxwell H, Wiesener MS, Chang G, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275.
62. Krieg M, Haas R, Brauch H, et al. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19:5435-5443.
63. Levy AP, Levy NS, Iliopulos O, et al. Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kid Intern. 1997;51:575-578.
64. Ivan M, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev. 2001;11:27-34.
65. Cybulski C, Krzystolik K, Murgia A, et al. Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J Med Genet. 2002;39:e38.
66. Ohh M, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein: new perspectives. Mol Med Today. 1999;5:257-263.
67. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Sem Cancer Biol. 2003;13:83-89.
68. Yao M, Tabuchi H, Nagashima Y, et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol. 2005;205:377-387.
69. Haase VH. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int. 2006;69:1302-1307.